Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2023-10-18

FDA Approved: ENTRESTO — Supplemental Application (Novartis Pharmaceuticals Corporation)

View source ↗

Summary

The FDA approved a supplemental application for ENTRESTO (sacubitril and valsartan) from Novartis Pharmaceuticals Corporation.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Entresto (sacubitril/valsartan)

Snippet

SUPPL AP for ENTRESTO (SACUBITRIL AND VALSARTAN)